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Developmental epilepsies are age-dependent seizure disorders for which genetic causes have been increasingly identified. Here we report
six unrelated individuals with mutations in salt-inducible kinase 1 (SIK1) in a series of 101 persons with early myoclonic encephalop-
athy, Ohtahara syndrome, and infantile spasms. Individuals with SIK1 mutations had short survival in cases with neonatal epilepsy
onset, and an autism plus developmental syndrome after infantile spasms in others. All six mutations occurred outside the kinase
domain of SIK1 and each of the mutants displayed autophosphorylation and kinase activity toward HDAC5. Three mutations generated
truncated forms of SIK1 that were resistant to degradation and also showed changes in sub-cellular localization compared to wild-type
SIK1. We also report the human neuropathologic examination of SIK1-related developmental epilepsy, with normal neuronal
morphology and lamination but abnormal SIK1 protein cellular localization. Therefore, these results expand the genetic etiologies of
developmental epilepsies by demonstrating SIK1 mutations as a cause of severe developmental epilepsy.Developmental epilepsies are age-dependent pediatric
seizure disorders that include early myoclonic encephalop-
athy,1,2Ohtahara syndrome,3,4malignantmigratingpartial
seizures of infancy,5 infantile spasms,6 and Lennox-Gastaut
syndrome.7 These disorders are often devastating,with out-
comes ranging from catastrophic neonatal epilepsy with
short survival to severe developmental disability, autism,
and life-long intractable epilepsy.8,9 Some children present
with early myoclonic encephalopathy or Ohtahara syn-
drome and then progress to infantile spasms and Lennox-
Gastaut syndrome as they mature.10,11 Mutations have
been identified in several genes in individualswithdevelop-
mental epilepsies, clustering in several biological pathways,
and it is common for persons with similar mutations in
genes such as ARX12,13 (MIM 308350), CDKL514,15 (MIM
300672), MEF2C16,17 (MIM 613443), and STXBP118,19
(MIM612164) topresentwith a spectrumofdevelopmental
epilepsies. However, in many the cause remains unknown.
As part of an ongoing genetic research program on devel-
opmental epilepsies, we performed genetic analysis in 101
individuals for whom clinically available molecular ge-
netic tests had failed to detect a mutation. The genetic
analysis was performed in accordance with informed con-
sent procedures approved by the Institutional Review
Boards at the University of Rochester Medical Center,
Washington University, and Seattle Children’s Hospital.
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682 The American Journal of Human Genetics 96, 682–690, April 2, 2In this study, we present six unrelated children with devel-
opmental epilepsies in whom mutations in the salt-induc-
ible kinase SIK1 (RefSeq accession number NM_173354.3)
were identified.
The first mutation in SIK1 was identified through
research-based exome sequencing in subject DB13-001, a
boy born at term who presented with seizures consistent
with early myoclonic encephalopathy at 20 min of life.
An EEG on the second day of life showed a discontinuous
background with burst suppression pattern (Figure 1A). He
developed intermittent myoclonic jerking movements,
and EEG on day 14 of life showed continuous high-ampli-
tude burst activity alternating with periods of voltage sup-
pression. Seizures did not respond to anticonvulsants, and
an extensive metabolic and genetic workup was negative.
He developed tonic seizures, burst suppression pattern per-
sisted at 8 months of life (Figure 1B), and myoclonic sei-
zures worsened. Brain MRI showed no structural malfor-
mations (Figures 1C and 1D). He died after complications
of a respiratory illness at 10 months of age. Further clinical
details are available in the Supplemental Data.
After clinical chromosomal microarray and epilepsy
gene panel sequencing was negative, we performed whole
exome sequencing (WES) on saliva-derived DNA from sub-
ject DB13-001 and both parents. We used the Agilent Sure-
Select 50 Mb whole exome capture kit, and 100 bp paired-
end reads were generated on an Illumina HiSeq2500
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Figure 1. EEG and Brain Imaging Data for Individuals with SIK1
Mutations
(A) Representative EEG tracings from subject DB13-001 at 10 days
of age showing burst suppression pattern with myoclonic activity,
consistent with a diagnosis of early myoclonic encephalopathy.
The AmCenter. Sequence was aligned to hg19 via BWA v.0.6.2 and
analyzed with Picard v.1.84, SAMtools v.0.1.18, and GATK
v.2.3-9. Mean read depth across the exome was 723 deter-
mined by GATK’s DepthOfCoverage walker, with 89% of
bases covered at more than 203. Annotation of variants
was performed with ANNOVAR, and de novo, autosomal-
recessive, and X-linked variants were identified and com-
mon variants in dbSNP 137 excluded via SOLVE-Brain
v.1.0.1. Common population variants were identified
with the NHLBI Exome Variant Server. Ensembl’s Variant
Effect Predictor provided SIFT and PolyPhen predictions
of pathogenicity. GERP scores were obtained from the
UCSC Genome Browser. Our analyses revealed four de
novo heterozygous and two compound heterozygous var-
iants in this individual (Table S1).
Of particular interest was a de novo heterozygous
c.895C>A (p.Pro287Thr) variant identified in SIK1 (RefSeq
NM_173354.3) and validated with standard bidirectional
Sanger sequencing (primer sequences provided in Table
S2) (Figure 2A). Though the p.Pro287Thr amino acid sub-
stitution in SIK1 was not predicted to be deleterious by
SIFTor PolyPhen, and the amino acid residue was not high-
ly conserved (Table 1), this genomic variant was not pre-
sent in >6,500 individuals in the NHLBI Exome Variant
Server or in the>61,000 individuals in the Exome Aggrega-
tion Consortium (ExAC) Browser. The other de novo het-
erozygous and compound heterozygous variants were
determined not to be compelling disease-causing candi-
dates, as detailed in Table S1.
SIK1 is a member of the AMP kinase subfamily with
several roles in the central nervous system including regu-
lation of the circadian clock20 and transcription of cortico-
tropin-releasing hormone in the hypothalamus.21 SIK1
abundance and activity are also increased by stimulation
with adrenocorticotrophic hormone (ACTH),22 which is
interestingly a first-line treatment for infantile spasms.23
ACTH triggers phosphorylation of SIK1 in a Protein Kinase
A (PKA)-dependent manner,24 resulting in movement of
activated SIK1 from the cytoplasm into the nucleus, where
it in turn phosphorylates HDAC5.25 Phosphorylation of
HDAC5 allows MEF2C transcriptional activity to pro-
ceed.26 MEF2C is a transcription factor important in both
dorsal and ventral neuronal developmental pathways17(B) At 8months of age, the EEG had not improved, with continued
burst suppression pattern associated with both myoclonic and
tonic seizures.
(C–J) MRI scans of subjects with SIK1 mutations showed subtle
abnormalities.
(C and D) Subject DB13-001 (p.Pro287Thr) at age 1 week showed
normal morphology.
(E and F) Subject IS13-013 (p.Gln614*) at age 12 years showed low
forehead, mild shortening of the corpus callosum, and mild atro-
phy of the cerebellar vermis.
(G and H) Subject LR05-086 (p.Gly636Ser) at 3 days of age with
increased extra-axial spaces and simplified gyral pattern in the
frontal lobes.
(I and J) Subject LR05-086 at age 16 months showed thinning of
the corpus callosum and asymmetric thinning of the whitematter.
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Figure 2. Heterozygous Mutations in SIK1
(A) Whole exome sequencing identified a c.895C>A variation re-
sulting in a p.Pro287Thr amino acid substitution, confirmed de
novo by Sanger sequencing of proband and parents.
(B–F) Unidirectional Sanger sequencing of the coding and intron-
exon boundaries of SIK1 in 100 subjects with developmental
epilepsy identified heterozygous mutations in 5 additional unre-
lated subjects, including c.1030G>T (p.Glu347*) (B), c.1231A>T
(p.Ser411Cys) (C), c.1840C>T (p.Gln614*) (D), c.1897C>T
(p.Gln633*) (E), and c.1906G>A (p.Gly636Ser) (F). SIK1 sequences
were compared to reference NM_173354.3. Primer sequences used
are provided in Table S2. Sequence variations not found in dbSNP
137 were then confirmed with bidirectional sequencing, and all
were confirmed de novo except for DB14-013 and IS09-018 where
parental DNA was unavailable.
(G) SIK1 contains a protein kinase domain (green), a ubiquitin
binding area (UBA), a proline-glutamate-serine-threonine (PEST)
domain, and a nuclear localization signal (NLS). Amino acid
substitutions (red) resulting frommutations in SIK1 occurred in re-
gions outside of known domains and in a cluster between the nu-
clear localization signal and the C terminus.
684 The American Journal of Human Genetics 96, 682–690, April 2, 2and its expression is decreased with deficiency of the early
forebrain transcription factor ARX.27 Loss-of-function mu-
tations in both ARX and MEF2C cause developmental epi-
lepsies including infantile spasms.12,16
SIK1 also regulates CREB1 transcriptional activity via
phosphorylation of TORC1 in an LKB1-dependent
manner,28 resulting in downstream effects on dendrite
growth during neuronal development.29 Recent transcrip-
tome studies of epilepsy have identified CREB-target genes
as involved in seizure pathogenesis.30 SIK1 is therefore
positioned to interact with the MEF2C pathway known
to be important in developmental epilepsies and the
CREB1 pathway implicated in epilepsy pathogenesis.
Because some authors have found mutation tolerance
scores helpful in determining a gene’s likelihood to cause
disease,31 we performed this evaluation for SIK1. With
the NHLBI EVS, we confirmed that SIK1 has 13 common
(mean allele frequency > 0.1%) variants out of 105 coding
variants, with a residual variance intolerance score (RVIS)
of 0.2626, which falls at the 35th percentile.32 Other au-
thors have arbitrarily chosen RVIS scores below the 25th
percentile as associated with pathogenicity in epileptic en-
cephalopathies.31 However, given that several known
epileptic encephalopathy genes have RVIS scores between
the 35th percentile (for FOXG1 [MIM 613454]) and the 58th
percentile (for MEF2C),32 we question the usefulness of
this statistical approach to identifying causal mutations
in genes, particularly in genes associated with rare but
very specific phenotypes.
To determine whether mutations in SIK1 are present in
other subjects with developmental epilepsies, we per-
formed Sanger sequencing of the coding regions of SIK1
in 100 subjects with developmental epilepsies and identi-
fied five additional mutations (Figures 2B–2F), including
three truncations and two missense mutations. The muta-
tions were de novo in all subjects where parental DNA was
available (four out of six children, including our initial pro-
band). None of these mutations were present in>6,500 in-
dividuals in the NHLBI EVS or in >61,000 individuals in
the ExAC Browser. The three nonsense mutations were
all predicted to result in a truncated protein. None of the
mutations identified in SIK1 in our subjects with develop-
mental epilepsies localized to the functional kinase
domain of the protein (Figure 2G) or other well-character-
ized regulatory regions.
A truncating mutation (c.1039G>T [p.Glu347*]; RefSeq
NM_173354.3) was identified in postmortem brain tissue
from subject DB14-013, a male infant who presented
with early myoclonic encephalopathy shortly after birth
with death at 3 months of age attributed to intractable sei-
zures. Three subjects presenting with infantile spasms
(EP-055, IS13-013, and IS09-018) subsequently developed
intractable epilepsy and an autism plus developmental dis-
order with absent speech, impaired socialization, and re-
petitive behaviors. Brain MRI in our subjects was either
normal (Figures 1C and 1D), showed mild hypoplasia of
the frontal lobes (Figures 1E and 1F), or in one subject015
Table 1. Summary of SIK1 Mutations Found in Six Subjects with Developmental Epilepsy
Subject
Genomic Coordinates
(hg19) cDNA
Amino Acid
Substitution Inheritance
Present
in EVS
Present
in ExAC SIFT/PolyPhen GERP
DB13-001 chr21: g.44840227G>T c.895C>A p.Pro287Thr de novo no no 0.22/0.081 1.55
DB14-013 chr21: g.44839819C>A c.1039G>T p.Glu347* ND no no – 5.16
EP-055 chr21: g.44839247T>A c.1231A>T p.Ser411Cys de novo no no 0.03/0.751 0.88
IS13-013 chr21: g.44837559G>A c.1840C>T p.Gln614* de novo no no – 4.07
IS09-018 chr21: g.44837502G>A c.1897C>T p.Gln633* ND no no – 4.07
LR05-086 chr21: g.44837493C>T c.1906G>A p.Gly636Ser de novo no no 0.46/0.093 0.48
Abbreviations are as follows: ND, no data because parental samples not available; EVS, NHLBI Exome Variant Server; ExAC, Exome Aggregation Consortium; SIFT,
Sorting Intolerant From Tolerant score; PolyPhen, Polymorphism Phenotyping score; GERP, Genomic Evolutionary Rate Profiling score.exhibited simplification of the gyral pattern and asym-
metric thinning of the white matter (Figures 1G–1J). These
are nonspecific findings commonly identified in individ-
uals with severe developmental disability. Genomic fea-
tures of the SIK1 mutations are summarized in Table 1
and further clinical details are in the Supplemental Data.
Because SIK1 is known to exhibit a high rate of turnover
in C2C12 cells and primary myoblasts,33 we first tested
whether the mutations identified affected protein stability.
Wild-type and variant forms of SIK1 were expressed in
HEK293Tcells by transfection, and the half-life of each pro-
tein determined by cycloheximide treatment and quantita-
tive immunoblotting. Our analysis revealed that the
c.1039G>T (p.Glu347*), c.1840C>T (p.Gln614*), and
c.1897C>T (p.Gln633*) proteins exhibited an increase in
stability compared to wild-type SIK1 (Figures 3A and 3B).
Phosphorylation of Thr473 by PKA increases the half-life
of SIK1, as does deleting an internal segment (residues
451–472) that resembles a PEST sequence.33 Thus, the
absence of these residues in the p.Glu347* protein probably
explains the increase inprotein stability. Evenmore striking
was the stability of the p.Gln614* and p.Gln633* mutants,
which might indicate that interdomain interactions are
critical for kinase stability and occur after the Ser575, but
might interact with the stability domains. The variant
SIK1 proteins p.Pro287Thr, p.Ser411Cys, and p.Gly636Ser
had turnover rates similar to that of wild-type SIK1.
We were next interested in whether the observed SIK1
mutations altered kinase activity. Using immunoprecipita-
tion-kinase assays, we evaluated both autophosphoryla-
tion of SIK1 and phosphorylation of HDAC5, a well-char-
acterized substrate of SIK1.26,34 We used recombinant
fragments of HDAC5 expressed as GST fusion proteins
that contained SIK1 phosphorylation sites Ser359 and
Ser498. A kinase-dead form of SIK1 (p.Lys56Met) was
used as a negative control in our activity assays.33 All
SIK1 variant proteins identified in individuals with devel-
opmental epilepsy demonstrated both autophosphoryla-
tion activity as well as the ability to phosphorylate
HDAC5 fragments in vitro (Figures 3C and 3D). These
data suggest that both variant and truncated SIK1 proteins
retain kinase activity.The AmWe then sought to determine whether variant and trun-
cated SIK1 proteins exhibited normal protein localization
patterns. In control conditions, wild-type and kinase-
dead p.Lys56Met SIK1 localize to a punctate pattern in
the nuclei of HEK293TN cells (Figures 4A and 4C).Whereas
the p.Pro287Thr, p.Ser411Cys, and p.Gly636Ser proteins
showed a similar pattern of punctate nuclear localization,
the p.Glu347*, p.Gln614*, and p.Gln633* truncated pro-
teins exhibited a broader pattern of localization within
the nucleus and in the cytoplasm. Because PKA is known
to regulate the expression and distribution of SIK1,22 we
treated HEK293TN cells with Forskolin (Fsk) and 3-isobu-
tyl-1-methylxanthine (IBMX) to activate PKA signaling
and determine its effects on the SIK1 mutant proteins. As
expected, wild-type SIK1 protein levels increased with pro-
longed Fsk/IBMX treatment and its localization shifted to
both the cytoplasm and the nucleus (Figure 4B). A similar
response to Fsk/IBMX was seen with the kinase-dead pro-
tein, although additional foci of protein product were
observed in the cytoplasm of these cells (Figures 4C and
4D). A similar observation was made in cells expressing
the p.Glu347* variant (Figures 4G and 4H). Additionally,
all three truncated proteins (p.Glu347*, p.Gln614*, and
p.Gln633*) showed a broader nuclear localization and
increased cytoplasmic localization compared to wild-type
SIK1 (Figures 4G–4L). The protein localization pattern for
the missense variant proteins after Fsk/IBMX treatment
resembled that of wild-type protein (Figures 4M–4R).
Furthermore, unlike the wild-type SIK1 protein, the
expression level of the p.Gln614* and p.Gln633* proteins
did not increase as much under Fsk/IBMX treatment,
although their overall expression levels were higher than
that of the wild-type protein or the missense mutants
(Figure S1). These data suggest that the missense SIK1 pro-
teins localized to the nucleus and shuttled to the cyto-
plasm with PKA stimulation, similar to wild-type protein.
The truncated proteins appear to have improper protein
localization and regulation, perhaps due to lack of a regu-
latory function normally contained in the C terminus
that promotes nuclear localization. Our biochemical and
cellular observations on the effects of these mutations are
summarized in Table 2.erican Journal of Human Genetics 96, 682–690, April 2, 2015 685
Figure 3. SIK1 Biochemical Studies
(A and B) To study the effects of SIK1muta-
tions in vitro, myc-SIK1 expression con-
structs were created by using human SIK1
amplified by PCR (Phusion Polymerase,
NEB) from a cDNA construct (Thermo
Scientific, clone ID, 4831049; accession,
BC038504). Primer sequences are available
in Table S3. Bothmyc and hSIK1 fragments
were cloned with T4 ligase (NEB) into
the XhoI and NotI site of a lentiviral
bi-cistronic farneslyated GFP construct
derived from a combination of pGIPZ
non-silencing (Thermo Scientific), pLVX-
IRES-tdTomato (Clontech), pDsRed-Mono-
mer-F (Clontech), and pIRES2-acGFP
(Clontech) vectors. Individual mutations
were introduced into SIK1 through PCR
amplification with Phusion polymerase
(NEB) and mutagenic primers, followed
by recombination with an In-Fusion HD
cloning system (Clontech). HEK293 cells
(Systems Biosciences) were cultured in
growth medium with DMEM/F12 ([þ]
L-glut and [þ] sodium bicarbonate from
Life Technologies), 5% FBS (Atlanta Biolog-
icals), 1% MEM NEAA (Life Technologies),
and 1% sodium pyruvate (Life Technolo-
gies) in a 5% CO2 humidified incubator
(Forma Scientific). SIK1 constructs were
transfected into cells with Fugene-6 (Prom-
ega) according to themanufacturer’s proce-
dure. Six hours after transfection, cells were
split into smaller plates, grown overnight, and given drug treatments (cycloheximide 100 mg/ml [Sigma]) for various durations. Cells
were washed once with PBS, lysed in SDS-loading buffer, heated at ~97C for 5 min, and then sonicated. Lysates were separated by
SDS-PAGE. Proteins were transferred onto nitrocellulose membrane for immunoblots. Membranes were blocked with 5% NFDM
(non-fat dry milk) in PBS-T solution and probed with an anti-myc primary antibody (9E10, DSHB), followed by Alexa Fluor 680-goat
anti-mouse-IgG (HþL) (Invitrogen). The signal was visualized and quantified with Odyssey (LICOR). The truncating p.Glu347*,
p.Gln614*, and p.Gln633* mutants showed increased protein stability (A) and prolonged half-life (B) compared to wild-type SIK1.
Themissensemutations were comparable to wild-type in their protein stability and half-life. SIK1 kinase activity (C andD) wasmeasured
by IP kinase assay with twoGST-tagged fragments of humanHDAC5 (243–276, 423–538; expressed in E. coli) that contain published sites
for SIK1 (Ser259, Ser498). Myc-tagged WT and SIK1 mutants were expressed in HEK293 cells, immunoprecipitated with anti-myc anti-
body preloaded onto protein G beads, and incubated with 1 mg substrate and 32P-ATP (100 mMATP total) in kinase buffer (50 mMHEPES
[pH 7], containing 5 mM MgCl2, 5 mM B-glycerophosphate, 150 mM Na3CO4, 1 mM DTT, and 1 mg/ml BSA) for 30 min at 30
C. SIK1
mutants p.Glu347*, p.Gln614*, and p.Gln633* express at higher levels, and therefore bead volume inputs were adjusted accordingly.
Kinase assay samples were subjected to SDS-PAGE and phosphorimaging. SIK1 (WT and mutants) does not phosphorylate GST under
these assay conditions (data not shown). Auto-phosphorylation and HDAC5 phosphorylation was observed for all mutants, compared
to wild-type SIK1 and the p.Lys56Met kinase-dead control (C and D).Because of the availability of a brain specimen from sub-
ject DB14-013 with the p.Glu347* SIK1 mutation, we were
able to compare SIK1 distribution in the presence of this
mutation as compared with control and mutation-nega-
tive epileptic infant brain. Brain weight for subject DB14-
013 was 584 g (average 516 g). On microscopic examina-
tion, no malformations were identified and neuronal
morphology and lamination were normal. SIK1 immuno-
fluorescence (IF) was detected in neurons and proximal
dendrites within the hippocampus and cortex (Figures
5A–5C). SIK1 IF was also seen in GFAPþ astrocytes in the
cortical white matter (Figures 5D–5F). However, the intra-
cellular distribution of SIK1 IF differed between control in-
fant brain, subject DB14-013 (SIK1 p.Glu347*), and that of
an infant with epileptic encephalopathy but normal SIK1
sequencing. In subject DB14-013, neuronal SIK1 IF was
predominant in the cytoplasm only, whereas in the other686 The American Journal of Human Genetics 96, 682–690, April 2, 2specimens it was equivalent in both the nucleus and cyto-
plasm (Figures 5G–5I). These findings indicated that SIK1
protein expression levels were not substantially altered
by the presence of the heterozygous p.Glu347* mutation
and that this SIK1 mutation did not result in gross abnor-
malities of brain formation or neuronal morphology.
However, alteration of SIK1 intracellular distribution was
detected, suggesting that nuclear localization of the
p.Glu347* mutant might be impaired, consistent with
our in vitro studies.
Our individuals with SIK1mutations had universally se-
vere outcomes. Subjects DB13-001 andDB14-013 both pre-
sented with early myoclonic encephalopathy and died in
infancy from intractable epilepsy with respiratory failure.
The other subjects had severe developmental impairment
with autistic features and continued refractory seizures,
and subject LR05-086 had respiratory failure requiring015
Figure 4. SIK1 Protein Localization Studies
To study protein localization, HEK293TN cells were plated on coverslips in a plasma cleaner and coated with poly-L-lysine (Sigma). The
day after plating, cells were transfected with CMV::myc-SIK1-IRES2-acGFP-F expression constructs via Lipofectamine 2000 according to
the manufacturer’s procedure. The day after transfection, cells received drug treatments (Forskolin 10 mM [Cayman Chemicals], IBMX
18 mM [Calbiochem]) for 3 hr. Cells were fixedwith a 4% paraformaldehyde PBS solution and blockedwith PBS containing 1% serum and
0.1% Triton X-100. Cells were incubated with a mouse anti-myc (9E10, DSHB) primary antibody diluted in blocking solution, followed
by a second incubation with goat anti-mouse Alexa594 conjugated secondary antibody (Invitrogen Molecular Probes) and Hoechst
33342 nuclear stain (Sigma) also diluted in blocking solution. Coverslips were mounted on slides with Mowiol and imaged with an
Olympus BX61 fluorescent microscope and Metamorph software. Wild-type SIK1 (A and B), the kinase-dead p.Lys56Met (C and D),
and empty vector (E and F) were used as controls. The mutant p.Glu347* (G and H), p.Gln614* (I and J), and p.Gln633* (K and L)
SIK1 proteins showed abnormal localization in both control (A, C, E, G, I, K, M, O, and Q) and Fsk/IBMX-treated conditions (B, D, F,
H, J, L, N, P, R). The missense mutants p.Pro287Thr (M and N), p.Ser411Cys (O and P), and p.Gly636Ser (Q and R) had localization pat-
terns resembling wild-type protein.tracheostomy placement and long-term ventilation. None
of the subjects with infantile spasms responded to ACTH.
Nearly all of the subjects required the placement of gastro-
stomy tubes for nutrition, and two of the four persons who
survived past infancy remained nonambulatory. Scoliosis
was present in two of the subjects. The clinical features
of SIK1-related developmental epilepsy are summarized
in Table 3 as well as in the Supplemental Data.
In conclusion, we identified de novo heterozygous mu-
tations in SIK1 in children presenting with developmental
epilepsies including early myoclonic encephalopathy, Oh-
tahara syndrome, and infantile spasms. Overall, our dataTable 2. Summary of Effects of SIK1 Mutations on Protein
Stability, Cellular Localization, and HDAC5 Phosphorylation
Subject
Amino Acid
Substitution
Increased
Protein
Stability
Abnormal
Cellular
Localization
HDAC5
Phosphorylation
DB13-001 p.Pro287Thr   þ
DB14-013 p.Glu347* þ þ þ
EP-055 p.Ser411Cys   þ
IS13-013 p.Gln614* þ þ þ
IS09-018 p.Gln633* þ þ þ
LR05-086 p.Gly636Ser   þ
The Amindicated that truncating mutations resulted in increased
protein stability and abnormal cellular localization and
that all mutant proteins were capable of phosphorylating
HDAC5. We also present human neuropathology of SIK1-
related developmental epilepsy and confirm our in vitro
observations of abnormal SIK1 protein cellular localization
in that specimen. Our study identified 6 SIK1mutations in
101 individuals sequenced, suggesting that this might be a
relatively common cause of developmental epilepsy and
that kinases involved in the nuclear control of gene tran-
scription can contribute to neurodevelopmental disease
and severe epilepsy.Supplemental Data
Supplemental Data include case reports, one figure, and three ta-
bles and can be found with this article online at http://dx.doi.
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Figure 5. SIK1 Brain Immunohistochem-
istry
Formalin-fixed human brain sections from
subject DB14-013 (p.Glu347* mutation)
and two other infants were obtained from
the NICHD Brain and Tissue Bank for
Developmental Disorders at the University
of Maryland, embedded in paraffin, and
sectioned at a thickness of 4 mm. Specimens
were deparaffinized by incubation in
xylene, followed by rehydration through
graded ethanol/water solutions and equili-
bration in PBS. Antigen retrieval was per-
formed by heating in 0.01M sodiumcitrate
(pH 6.0) in a 90C water bath for 45 min.
Specimens were then blocked in PBS with
10% donkey serum, 0.1% Triton X-100,
and 2%BSA for 30min and incubated over-
night at 4C in primary antibodies diluted
in blocking solution. The SIK1 primary
antibody (M01, clone 2C12, Abnova) is a
mouse monoclonal IgG2a directed against
an epitope mapping to the N-terminal 100
amino acids of human SIK1. Other primary
antibodies included goat polyclonal MAP2
and GFAP (Santa Cruz). Slides were then
incubated in fluorescent secondary anti-
bodies at room temperature for 2 hr. After
incubation in DAPI nuclear counterstain
and Sudan Black to block endogenous
fluorescence, sections were examined and
photographed with a Nikon Eclipse Ni-U
epifluorescence microscope.
(A–C) SIK1 immunofluorescence (IF) in
subject DB14-013 was detected in
neuronal somas and proximal dendrites
within the dentate gyrus and hilus (A) and CA3 of the hippocampus (B), as well as in the temporal cortex (C).
(D–F) SIK1 expression in GFAPþ astrocytes in white matter of the temporal cortex in subject DB14-013, illustrated by staining for SIK1
(D), GFAP (E), or both (F). Scale bar represents 100 mm.
(G–I) SIK1 IF in temporal cortex of a control infant (G), subject DB14-013 (H), and an epileptic infant with normal SIK1 sequencing
(I). Pyramidal neurons exhibited both nuclear and cytoplasmic SIK IF in the control and epileptic subjects, but localization predom-
inantly in the cytoplasm in subject DB14-013. Scale bars represent 50 mm.would like to acknowledge the University of Rochester Genomics
Research Center for sequencing support, and the University of Ro-
chester Center for Integrated Research Computing for providingTable 3. Genotype-Phenotype Correlations in Six Subjects Presenting
Subject
Amino Acid
Substitution
Presenting
Epilepsy
Death in
Infancy ID
Absent
Language
Impaired
Socializati
DB13-001 p.Pro287Thr EME þ NA NA NA
DB14-013 p.Glu347* EME þ NA NA NA
EP-055 p.Ser411Cys ISS  þ þ þ
IS13-013 p.Gln614* ISS  þ þ þ
IS09-018 p.Gln633* ISS  þ þ þ
LR05-086 p.Gly636Ser OS  þ þ þ
Abbreviations are as follows: EME, early myoclonic encephalopathy; OS, Ohtahara
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Timothy McKinsey (University of Colorado, Denver) for HDAC5
constructs.with Developmental Epilepsy and SIK1 Mutations
on
Repetitive
Behaviors
Non-
ambulatory
Gastrostomy
Tube
Respiratory
Failure
Other
Findings
NA NA þ þ 
NA NA þ þ 
þ    anomalous
pulmonary
arterial
circulation
þ  þ  disordered
sleep,
breath-holding
spells,
scoliosis
þ þ þ  
þ þ þ þ diabetes
insipidus,
scoliosis
syndrome; ISS, infantile spasms; ID, intellectual disability; NA, not applicable.
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